JP5587215B2 - 併用療法 - Google Patents

併用療法 Download PDF

Info

Publication number
JP5587215B2
JP5587215B2 JP2010549109A JP2010549109A JP5587215B2 JP 5587215 B2 JP5587215 B2 JP 5587215B2 JP 2010549109 A JP2010549109 A JP 2010549109A JP 2010549109 A JP2010549109 A JP 2010549109A JP 5587215 B2 JP5587215 B2 JP 5587215B2
Authority
JP
Japan
Prior art keywords
zinc
trimethoprim
viral
infection
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010549109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513356A (ja
JP2011513356A5 (fr
Inventor
マグディ、エル‐ハバル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magdi El Habbal
Original Assignee
Magdi El Habbal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magdi El Habbal filed Critical Magdi El Habbal
Publication of JP2011513356A publication Critical patent/JP2011513356A/ja
Publication of JP2011513356A5 publication Critical patent/JP2011513356A5/ja
Application granted granted Critical
Publication of JP5587215B2 publication Critical patent/JP5587215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010549109A 2008-03-03 2009-02-27 併用療法 Active JP5587215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0803948.9 2008-03-03
GBGB0803948.9A GB0803948D0 (en) 2008-03-03 2008-03-03 Combination therapy
PCT/EP2009/052394 WO2009109531A2 (fr) 2008-03-03 2009-02-27 Polythérapie

Publications (3)

Publication Number Publication Date
JP2011513356A JP2011513356A (ja) 2011-04-28
JP2011513356A5 JP2011513356A5 (fr) 2012-04-12
JP5587215B2 true JP5587215B2 (ja) 2014-09-10

Family

ID=39315874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549109A Active JP5587215B2 (ja) 2008-03-03 2009-02-27 併用療法

Country Status (11)

Country Link
US (1) US10045984B2 (fr)
EP (1) EP2257292B1 (fr)
JP (1) JP5587215B2 (fr)
CN (1) CN101998856A (fr)
CA (1) CA2754281C (fr)
CY (1) CY1115555T1 (fr)
DK (1) DK2257292T3 (fr)
ES (1) ES2507570T3 (fr)
GB (1) GB0803948D0 (fr)
PT (1) PT2257292E (fr)
WO (1) WO2009109531A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2740657C1 (ru) * 2020-05-15 2021-01-19 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная композиция
NL2028566B1 (nl) * 2021-06-29 2023-01-09 Simons Care Innovation Group B V Een zinkzout huidpleister en werkwijzen
JP7287730B2 (ja) * 2021-10-12 2023-06-06 ローバル株式会社 ウイルスを不活化可能な高濃度亜鉛末塗料

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125610A (en) * 1977-07-27 1978-11-14 Bristol-Myers Company Antibacterial compositions
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto

Also Published As

Publication number Publication date
WO2009109531A3 (fr) 2009-11-12
DK2257292T3 (da) 2014-09-29
PT2257292E (pt) 2014-10-22
CN101998856A (zh) 2011-03-30
CA2754281A1 (fr) 2009-09-11
GB0803948D0 (en) 2008-04-09
JP2011513356A (ja) 2011-04-28
ES2507570T3 (es) 2014-10-15
US10045984B2 (en) 2018-08-14
EP2257292B1 (fr) 2014-07-16
CA2754281C (fr) 2016-12-06
CY1115555T1 (el) 2017-01-04
WO2009109531A2 (fr) 2009-09-11
US20110045070A1 (en) 2011-02-24
EP2257292A2 (fr) 2010-12-08

Similar Documents

Publication Publication Date Title
CN110325187B (zh) N-氨基甲酰亚胺基-5-(1-甲基-1h-吡唑-4-基)-2-萘甲酰胺在制备治疗流感的药物中的用途
AU2007345952C1 (en) Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
EP2983667B1 (fr) Composés de liaison à nhe3 et procédés d'inhibition du transport de phosphate
EP2799071B1 (fr) Lévocétirizine et montélukast pour le traitement de la grippe et le rhume
TW200819430A (en) Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
EP2515889A2 (fr) Composition antivirale synergique et utilisation associée
JP2007291067A (ja) 医薬組成物
CA2991156A1 (fr) Compositions et methodes de traitement d'une infection virale
JP5587215B2 (ja) 併用療法
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
WO2016120787A1 (fr) N-acétylcystéine destinée à être administrée par voie orale dans le traitement d'infections des voies respiratoires supérieures et de symptômes associés
US20180110774A1 (en) Compositions and methods for treatment of pulmonary hypertension
RU2237475C1 (ru) Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты)
WO2007040188A1 (fr) Composition médicinale pour inhiber la formation excessive de cellules caliciformes
JP2023016055A (ja) インフルエンザおよび重篤なインフルエンザ状態を有する対象者における、置換された多環性ピリドン誘導体およびそのプロドラッグを使用したインフルエンザの治療
CA3241241A1 (fr) Association pharmaceutique pour le traitement de l'infection respiratoire causee par le sars-cov-2
WO2015054359A1 (fr) Procédés et compositions pour le traitement symptomatique du rhume
JP2021161105A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
JP2008515824A (ja) ２−イミダゾリン構造を有するα−交感神経興奮薬の新規な使用
JP2006117569A (ja) ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬
JP5463019B2 (ja) エピナスチン類とエフェドリン類とを含有する気道杯細胞過形成を抑制するための医薬組成物
TW200838534A (en) Treatment for irritable bowel syndrome
JPS5888311A (ja) 呼吸器疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140723

R150 Certificate of patent or registration of utility model

Ref document number: 5587215

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250